IL-6 in the plasma binds to soluble IL-6RA and this complex has elevated agonist activity at activating tumor cell surface IL-6RA, however, gp130 in the plasma binds to the IL-6/sIL-6RA complex and quenches the ability of the protein complex to act as an agonist [40]. This evidence concerns the gene IL6 and neoplasm.